I suggest that everyone stop focusing on the difference in the results between the USA and Australia and start focusing on the patient selection and/or scoring. Given the numbers in the trials (too large to just be random noise) these results look to be due to a difference in the patients, or in they way they are assessed.
I suspect that the problem is in the way the patients were assessed in the USA.
Ann: Botanix Announces BTX 1503 Data and Progression to Phase 3, page-197
-
- There are more pages in this discussion • 206 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.005(1.33%) |
Mkt cap ! $687.8M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 38.0¢ | 36.0¢ | $2.725M | 7.415M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 70075 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 422900 | 17 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |